BLOG

Moving Quickly but Smartly from R&D to Commercialization

In December, Rocket Pharma presented results from a Phase I trial on RP-L102, a gene therapy for Fanconi anemia. Unlike earlier trials, these new results were from patients treated with a commercial-grade version of the product.